To determine the clinical significance of our findings, we then performed analyses with serum and tumors obtained from 23 HER2-positive breast cancer patients who responded well to Herceptin-containing treatments and 17 HER2-positive breast cancer patients poorly responded to the treatments. This evidence concerns the gene ERBB2 and breast cancer.